Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

2022

CSCC

Author

Gross, Neil D., Miller, David M. et al.

Published

September 11, 2022

Doi

10.1056/NEJMoa2209813

Abstract

We present a prosepective study of neoadjuvant cemiplimab in high-risk resectable CSCC. This study was published in the New England Journal of Medicine in September 2022.

Metrics

Study Reference

Gross, Neil D., David M. Miller, Nikhil I. Khushalani, Vasu Divi, Emily S. Ruiz, Evan J. Lipson, Friedegund Meier, et al. 2022. “Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.” New England Journal of Medicine 387 (17): 1557–68. https://doi.org/10.1056/nejmoa2209813.